Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Clinical trials

Ebola trials fast-tracked in Africa

Jeremy Farrar, director of the Wellcome Trust on ebola trials being fast-tracked in Africa

Source: Wellcome Trust

Jeremy Farrar, director of the Wellcome Trust which is funding clinical trial research into Ebola therapies, says it is a “huge challenge” to carry out trials under such difficult conditions

Experimental drugs for Ebola are to be fast-tracked in clinical trials being established in West African states fighting the epidemic, which has so far cost almost 3,000 lives. 

The sites for the trials and their design have yet to be decided but it has been agreed that the drugs will be tested on patients who have already contracted the disease. 

The initiative, backed by the World Health Organization (WHO) and funded with a £3.2m grant from the Wellcome Trust, has been established by an international consortium led by Peter Horby, associate professor of infectious diseases and global health at the University of Oxford. 

An independent panel has been appointed by WHO to choose which drugs under development should be used for the fast-track trials. Drug companies which are already developing treatments – Mapp Biopharmaceutical, Sarepta and Tekmira – are providing WHO with critical data to help inform the decision. 

“It is a huge challenge to carry out clinical trials under such difficult conditions, but ultimately this is the only way we will ever find out whether any new Ebola treatments actually work,” said Jeremy Farrar, director of the Wellcome Trust.

The announcement comes after WHO agreed in August 2014 that Ebola experimental drugs could ethically be made available to treat or prevent the spread of the disease.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066628

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.